

SUPPLEMENTARY INFORMATION

Photo-Induced Glycosylation Using Reusable Organophotoacids

Ryosuke Iwata, Kanjiro Uda, Daisuke Takahashi and Kazunobu Toshima*

*Department of Applied Chemistry, Faculty of Science and Technology, Keio University,
3-14-1 Hiyoshi, Kohoku-ku, Yokohama 223-8522, Japan*


Page	Contents
S2 . . .	General experimental methods
S2 . . .	General procedure for glycosylations
S3 . . .	Characterization of glycosides 9 , 17-21 , 25-27
S11 . . .	References
S12 . . .	¹ H and ¹³ C NMR spectra

General experimental methods


Melting points were determined on a micro hot-stage (Yanako MP-S3). Optical rotations were measured on a JASCO P-2200 polarimeter. ^1H and ^{13}C NMR spectra were recorded on a JEOL ECA-500 (500 MHz) spectrometer. ^1H NMR data are reported as follows; chemical shift in parts per million (ppm) downfield or upfield from tetramethylsilane (δ 0.00), CDCl_3 (δ 7.26) or acetone- d_6 (δ 2.05) integration, multiplicity (br = broad, s = singlet, d = doublet, t = triplet and m = multiplet) and coupling constants (Hz). ^{13}C chemical shifts are reported in ppm downfield or upfield from CDCl_3 (δ 77.00) or acetone- d_6 (δ 29.8). For ^1H NMR analysis, prime number was used for assigning number to sugar carbon. ESI-TOF Mass spectra were measured on a Waters LCT premier XE. Silica gel TLC and column chromatography were performed on Merck TLC 60F-254 (0.25 mm) and Silica Gel 60 N (spherical, neutral, 40-50 μm) (Kanto Chemical Co., Inc.), respectively.

General procedure for glycosylations by using organophotoacids


To a stirred solution of glycosyl donor (0.1 mmol) and glycosyl acceptor (0.2~0.3 mmol) in Et_2O (0.5 M) was added organophotoacid **2** (0.03 mmol) or **5** (0.01 mmol). After stirring for 4 h under the photoirradiation using a UV lamp (365 nm, 12 mW/cm^2), the mixture was concentrated in vacuo. The purification of the residue by flash column chromatography gave the corresponding glycoside, and **2** or **5** was recovered.




Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranoside (9 α)¹: Colorless syrup; R_f 0.35 (4/1 *n*-hexane/EtOAc); $[\alpha]_D^{27} +41.1^\circ$ (*c* 0.99, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.85-1.00 (2H, m), 1.09-1.33 (3H, m), 1.60-1.88 (6H, m), 3.20 (1H, dd, $J = 9.5$ and 6.0 Hz, OCH₂), 3.42 (1H, dd, $J = 9.5$ and 7.5 Hz, OCH₂), 3.55 (1H, dd, $J = 9.5$ and 3.5 Hz, H-2), 3.58-3.82 (4H, m), 3.97 (1H, dd, $J = 9.5$ and 9.5 Hz, H-3), 4.47 and 4.61 (2H, ABq, $J = 12.5$ Hz, ArCH₂), 4.47 and 4.83 (2H, ABq, $J = 11.0$ Hz, ArCH₂), 4.64 and 4.76 (2H, ABq, $J = 12.0$ Hz, ArCH₂), 4.73 (1H, d, $J = 3.5$ Hz, H-1), 4.81 and 4.99 (2H, ABq, $J = 10.5$ Hz, ArCH₂), 7.11-7.16 (2H, m, ArH), 7.22-7.40 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.7, 25.8, 26.6, 30.0 \times 2, 37.6, 68.5, 70.0, 73.0, 73.4, 73.9, 75.1, 75.6, 77.8, 80.3, 82.1, 97.1, 127.6, 127.7 \times 2, 127.9 \times 2, 128.0, 128.3, 128.4 \times 2, 138.0, 138.3, 138.4, 139.0; HRMS (ESI-TOF) m/z 659.3329 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).




Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranoside (9 β)¹: White solid; R_f 0.40 (4/1 *n*-hexane/EtOAc); $[\alpha]_D^{27} +4.2^\circ$ (*c* 0.99, CHCl₃); mp 98.0-99.0 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.90-1.06 (2H, m), 1.08-1.34 (3H, m), 1.58-1.92 (6H, m), 3.32 (1H, dd, $J = 9.5$ and 7.0 Hz, OCH₂), 3.40-3.49 (2H, m), 3.53-3.77 (4H, m), 3.79 (1H, dd, $J = 9.5$ and 6.0 Hz, OCH₂), 4.37 (1H, d, $J = 7.5$ Hz, H-1), 4.52 and 4.81 (2H, ABq, $J = 11.0$ Hz, ArCH₂), 4.56 and 4.62 (2H, ABq, $J = 12.0$ Hz, ArCH₂), 4.71 and 4.96 (2H, ABq, $J = 11.0$ Hz, ArCH₂), 4.78 and 4.92 (2H, ABq, $J = 10.5$ Hz, ArCH₂), 7.13-7.18 (2H, m, ArH), 7.22-7.38 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.8 \times 2, 26.5, 29.9, 30.1, 38.1, 69.0, 73.4, 74.8, 74.9, 75.0, 75.7 \times 2, 78.0, 82.3, 84.7, 103.8, 127.6, 127.7, 127.8, 128.1, 128.2, 128.3, 128.4, 138.1, 138.2, 138.5, 138.6; HRMS (ESI-TOF) m/z 659.3316 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).




***n*-Octyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranoside (17 α)¹**: Colorless syrup; R_f 0.45 (6/1 *n*-hexane/EtOAc); $[\alpha]_D^{33} +37.6^\circ$ (*c* 1.10, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.83-0.92 (3H, m), 1.20-1.40 (10H, m), 1.58-1.67 (2H, m), 3.41 (1H, dt, *J* = 10.0 and 6.5 Hz, OCH₂), 3.55 (1H, dd, *J* = 9.5 and 4.0 Hz, H-2), 3.58-3.68 (1H, m), 3.62 (1H, dd, *J* = 10.0 and 4.0 Hz, H-6), 3.63 (1H, dd, *J* = 9.5 and 4.5 Hz, H-4), 3.72 (1H, dd, *J* = 10.0 and 4.0 Hz, H-6), 3.78 (1H, ddd, *J* = 10.0, 5.0 and 4.0 Hz, H-5), 3.98 (1H, dd, *J* = 9.5 and 9.5 Hz, H-3), 4.47 and 4.61 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.47 and 4.83 (2H, ABq, *J* = 10.5 Hz, ArCH₂), 4.65 and 4.78 (2H, ABq, *J* = 12.5 Hz, ArCH₂), 4.75 (1H, d, *J* = 3.5 Hz, H-1), 4.81 and 4.99 (2H, d, *J* = 11.0 Hz, ArCH₂), 7.10-7.16 (2H, m, ArH), 7.22-7.39 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 14.1, 22.7, 26.2, 29.2, 29.4, 31.8, 68.2, 68.5, 70.0, 73.1, 73.4, 75.1, 75.7, 77.8, 80.1, 82.1, 96.9, 127.5, 127.6, 127.7, 127.8, 127.9 \times 2, 128.0, 128.4 \times 2, 138.0, 138.3, 138.4, 138.9; HRMS (ESI-TOF) *m/z* 675.3634 (675.3662 calcd for C₄₂H₅₂O₆Na [M+Na]⁺).




***n*-Octyl 2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranoside (17 β)¹**: White solid; R_f 0.50 (6/1 *n*-hexane/EtOAc); $[\alpha]_D^{33} +7.0^\circ$ (*c* 0.46, CHCl₃); mp 33.5-34.0 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.82-0.93 (3H, m), 1.19-1.46 (10H, m), 1.58-1.74 (2H, m), 3.44 (1H, dd, *J* = 9.0 and 7.5 Hz, H-2), 3.42-3.55 (2H, m), 3.57 (1H, dd, *J* = 9.0 and 9.0 Hz, H-3), 3.63-3.71 (1H, m), 3.64 (1H, dd, *J* = 9.0 and 9.0 Hz, H-4), 3.75 (1H, dd, *J* = 10.5 and 2.0 Hz, H-6), 3.96 (1H, dt, *J* = 9.5 and 6.0 Hz, OCH₂), 4.38 (1H, d, *J* = 8.0 Hz, H-1), 4.52 and 4.81 (2H, ABq, *J* = 10.5 Hz, ArCH₂), 4.56 and 4.61 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.71 and 4.96 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 4.78 and 4.93 (2H, ABq, *J* = 11.0 Hz, ArCH₂), 7.13-7.18 (2H, m, ArH), 7.23-7.38 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 14.1, 22.7, 26.2, 29.3, 29.4, 29.8, 31.8, 69.0, 70.2, 73.4, 74.8 \times 2, 75.0, 75.7, 77.9, 82.3, 84.7, 103.6, 127.6 \times 2, 127.7, 127.9, 128.0, 128.1, 128.3, 128.4 \times 2, 138.1, 138.2, 138.5, 138.6; HRMS (ESI-TOF) *m/z* 675.3640 (675.3662 calcd for C₄₂H₅₂O₆Na [M+Na]⁺).




Isopropyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranoside (18 α)¹: Colorless syrup; R_f 0.60 (60/1 chloroform/EtOAc); $[\alpha]_D^{27} +37.2^\circ$ (c 1.38, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 1.17 and 1.22 (each 3H, d, J = 6.0 Hz, CH₃), 3.55 (1H, dd, J = 10.0 and 3.5 Hz, H-2), 3.61 (1H, dd, J = 10.0 and 2.0 Hz, H-6), 3.64 (1H, dd, J = 9.8 and 8.5 Hz, H-4), 3.73 (1H, dd, J = 10.5 and 3.5 Hz, H-6), 3.84 (1H, ddd, J = 10.0, 3.5 and 1.5 Hz, H-5), 3.89 (1H, qq, J = 6.0 Hz, OCH), 3.99 (1H, dd, J = 9.0 and 9.0 Hz, H-3), 4.46 and 4.61 (2H, ABq, J = 12.0 Hz, ArCH₂), 4.47 and 4.83 (2H, ABq, J = 10.5 Hz, ArCH₂), 4.65 and 4.77 (2H, ABq, J = 12.0 Hz, ArCH₂), 4.81 and 5.00 (2H, ABq, J = 10.5 Hz, ArCH₂), 7.10-7.16 (2H, m, ArH), 7.22-7.41 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 21.1, 23.2, 68.5, 69.0, 70.0, 73.1, 73.4, 75.1, 75.7, 77.9, 79.9, 82.1, 94.8, 127.5, 127.6, 127.7, 127.8, 127.9 \times 2, 128.0, 128.2, 128.3, 128.4 \times 2, 138.0, 138.2, 138.3, 139.0; HRMS (ESI-TOF) 605.2849 (605.2879 calcd for C₃₇H₄₂O₆Na [M+Na]⁺).




Isopropyl 2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranoside (18 β)¹: White solid; R_f 0.46 (5/1 *n*-hexane/EtOAc); $[\alpha]_D^{27} +10.3^\circ$ (c 0.64, CHCl₃); mp 109.5-110.5 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.24 and 1.32 (each 3H, d, J = 6.0 Hz, CH₃), 3.43 (1H, dd, J = 9.0 and 7.5 Hz, H-4), 3.44 (1H, ddd, J = 9.0, 4.0 and 2.0 Hz, H-5), 3.54 (1H, dd, J = 9.0 and 9.0 Hz, H-3), 3.63 (1H, dd, J = 9.0 and 7.5 Hz, H-2), 3.65 (1H, dd, J = 10.0 and 4.0 Hz, H-6), 3.74 (1H, dd, J = 11.0 and 2.0 Hz, H-6), 4.02 (1H, qq, J = 6.0 Hz, OCH), 4.46 (1H, d, J = 7.5 Hz, H-1), 4.53 and 4.82 (2H, ABq, J = 11.0 Hz, ArCH₂), 4.58 and 4.61 (2H, ABq, J = 12.5 Hz, ArCH₂), 4.70 and 4.97 (2H, ABq, J = 11.0 Hz, ArCH₂), 4.78 and 4.92 (2H, ABq, J = 11.0 Hz, ArCH₂), 7.14-7.19 (2H, m, ArH), 7.23-7.39 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 22.2, 23.7, 69.2, 72.4, 73.4, 74.8, 75.0, 75.7, 78.0, 82.3, 84.8, 102.2, 127.5, 127.6 \times 2, 127.7 \times 2, 127.9, 128.0, 128.2, 128.3, 128.4, 138.1, 138.3, 138.5, 138.7; HRMS (ESI-TOF) 605.2907 (605.2879 calcd for C₃₇H₄₂O₆Na [M+Na]⁺).



Cyclohexyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranoside (19 α)¹: Colorless syrup; R_f 0.64 (60/1 chloroform/EtOAc); $[\alpha]_D^{27} +51.0^\circ$ (c 1.71, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 1.12-1.60 (6H, m), 1.69-1.96 (4H, m), 3.51-3.68 (1H, m), 3.55 (1H, dd, J = 10.0 and 3.5 Hz, H-2), 3.62 (1H, dd, J = 11.0 and 2.0 Hz, H-6), 3.63 (1H, dd, J = 10.0 and 9.5 Hz, H-4), 3.74 (1H, dd, J = 10.5 and 4.0 Hz, H-6), 3.88 (1H, ddd, J = 10.0, 4.0 and 2.0 Hz, H-5), 4.00 (1H, dd, J = 9.0 and 9.0 Hz, H-3), 4.46 and 4.61 (2H, ABq, J = 12.0 Hz, ArCH₂), 4.46 and 4.83 (2H, ABq, J = 10.5 Hz, ArCH₂), 4.66 and 4.74 (2H, ABq, J = 12.0 Hz, ArCH₂), 4.81 and 5.00 (2H, ABq, J = 10.5 Hz, ArCH₂), 4.95 (1H, d, J = 3.5 Hz, H-1), 7.11-7.16 (2H, m, ArH), 7.22-7.38 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 24.1, 24.4, 25.6, 31.4, 33.3, 68.6, 70.0, 72.9, 73.4, 75.1, 75.3, 75.6, 77.3, 77.9, 80.0, 82.1, 94.7, 127.5, 127.6, 127.7, 127.8 \times 2, 127.9, 128.0, 128.1, 128.3 \times 2, 138.0, 138.2, 138.3, 139.0; HRMS (ESI-TOF) 645.3193 (645.3192 calcd for C₄₀H₄₆O₆Na [M+Na]⁺).




Cyclohexyl 2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranoside (19 β)¹: White solid; R_f 0.48 (60/1 chloroform/EtOAc); $[\alpha]_D^{27} +8.7^\circ$ (c 0.90, CHCl₃); mp 104-106 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.19-1.60 (6H, m), 1.70-1.81 (2H, m), 1.90-2.09 (2H, m), 3.44 (1H, dd, J = 9.5 and 9.5 Hz, H-3), 3.45 (1H, ddd, J = 9.0, 5.0 and 1.5 Hz, H-5), 3.51-3.79 (2H, m), 3.62 (1H, dd, J = 9.0 and 8.0 Hz, H-2), 3.75 (1H, dd, J = 11.0 and 2.0 Hz, H-6), 4.50 (1H, d, J = 8.0 Hz, H-1), 4.54 and 4.82 (2H, ABq, J = 11.5 Hz, ArCH₂), 4.56 and 4.61 (2H, ABq, J = 12.5 Hz, ArCH₂), 4.71 and 4.99 (2H, ABq, J = 10.5 Hz, ArCH₂), 4.78 and 4.92 (2H, ABq, J = 10.5 Hz, ArCH₂), 7.15-7.20 (2H, m, ArH), 7.24-7.38 (18H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 24.0, 24.1, 25.6, 32.0, 33.8, 69.2, 73.4, 74.8 \times 2, 75.0, 75.7, 77.8, 78.0, 82.3, 84.8, 101.9, 127.5 \times 2, 127.6, 127.7 \times 2, 127.9, 128.0, 128.2, 128.3 \times 2, 128.4, 138.1, 138.3, 138.5, 138.7; HRMS (ESI-TOF) m/z 645.3163 (645.3192 calcd for C₃₈H₄₄O₆Na [M+Na]⁺).




20 α

2-Phenylethyl 2,3,4,6-tetra-*O*-benzyl- α -D-glucopyranoside (20 α): Colorless syrup; R_f 0.50 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{24} +45.3^\circ$ (*c* 1.26, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 2.88-3.00 (2H, m), 3.50-3.71 (6H, m), 3.78-3.83 (1H, m), 3.97 (1H, dd, *J* = 9.5 and 9.5 Hz, H-3), 4.43 and 4.57 (2H, ABq, *J* = 12.5 Hz, ArCH₂), 4.45 and 4.81 (2H, ABq, *J* = 11.0 Hz, ArCH₂), 4.62 and 4.76 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.77 (1H, d, *J* = 3.5 Hz, H-1), 4.82 and 4.98 (2H, ABq, *J* = 10.5 Hz, ArCH₂), 7.10-7.16 (2H, m, ArH), 7.16-7.40 (23H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 36.0, 68.4, 68.7, 70.1, 73.2, 73.4, 74.9, 75.7, 77.6, 80.0, 82.0, 96.8, 126.3, 127.5, 127.6 \times 2, 127.7, 127.8 \times 2, 128.0 \times 2, 128.3, 128.4 \times 2, 129.0, 137.9, 138.3 \times 2, 138.6, 138.8; HRMS (ESI-TOF) *m/z* 667.3035 (667.3036 calcd for C₄₂H₄₄O₆Na [M+Na]⁺).




20 β


2-Phenylethyl 2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranoside (20 β): White solid; R_f 0.55 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{25} +12.3^\circ$ (*c* 1.16, CHCl₃); mp 65.0-66.5 °C; ¹H NMR (500 MHz, CDCl₃) δ 2.93-3.03 (2H, t, *J* = 7.0 Hz, ArCH₂), 3.40-3.49 (2H, m), 3.55-3.82 (5H, m), 4.21 (1H, m), 4.41 (1H, d, *J* = 8.0 Hz, H-1), 4.52 and 4.81 (2H, ABq, *J* = 11.0 Hz, ArCH₂), 4.54 and 4.61 (2H, ABq, *J* = 12.5 Hz, ArCH₂), 4.60 and 4.75 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 4.77 and 4.91 (2H, ABq, *J* = 11.0 Hz, ArCH₂), 7.12-7.39 (25H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 36.3, 68.9, 70.6, 73.5, 74.7, 74.8, 75.0, 75.7, 77.8, 82.2, 84.6, 103.6, 126.3, 127.6 \times 2, 127.7, 127.8 \times 2, 128.0, 128.1, 128.3 \times 2, 128.4, 128.9, 138.1 \times 2, 138.4, 138.6, 138.7; HRMS (ESI-TOF) *m/z* 667.3055 (667.3036 calcd for C₄₂H₄₄O₆Na [M+Na]⁺).



Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(2',3',4',6'-tetra-*O*-benzyl- α -D-glucopyranosyl)- α -D-glucopyranoside (21 α)¹: White solid; R_f 0.35 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{28} +57.1^\circ$ (*c* 0.91, CHCl₃); mp 102.5-103.5 °C; ¹H NMR (500 MHz, CDCl₃) δ 3.35 (3H, s, OMe), 3.44 (1H, dd, $J = 9.5$ and 3.5 Hz), 3.49-3.86 (9H, m), 3.90-4.03 (2H, m), 4.37-4.48 (2H, m), 4.53-4.67 (5H, m), 4.55 (1H, d, $J = 3.5$ Hz, H-1), 4.71 (1H, ABq, $J = 12.0$ Hz, ArCH₂), 4.77 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 4.81 (1H, ABq, $J = 10.5$ Hz, ArCH₂), 4.82 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 4.92 (1H, ABq, $J = 11.5$ Hz, ArCH₂), 4.93 (1H, ABq, $J = 11.5$ Hz, ArCH₂), 4.96 (1H, ABq, $J = 11.5$ Hz, ArCH₂), 4.98 (1H, d, $J = 4.0$ Hz, H-1'), 7.08-7.13 (2H, m, ArH), 7.20-7.36 (33H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 55.1, 66.0, 68.4, 70.2, 70.3, 72.4, 73.4 \times 2, 74.9 \times 2, 75.5, 75.7, 77.6, 77.7, 79.9, 80.1, 81.7, 82.1, 97.2, 97.9, 127.5, 127.6, 127.7, 127.9 \times 2, 128.0 \times 2, 128.3 \times 3, 128.4, 138.0, 138.2, 138.4 \times 2, 138.8; HRMS (ESI-TOF) m/z 1009.4470 (1009.4503 calcd for C₆₂H₆₆O₁₁Na [M+Na]⁺).




Methyl 2,3,4-tri-*O*-benzyl-6-*O*-(2',3',4',6'-tetra-*O*-benzyl- β -D-glucopyranosyl)- α -D-glucopyranoside (21 β)¹: White solid; R_f 0.35 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{27} +17.4^\circ$ (*c* 1.13, CHCl₃); mp 133-134 °C; ¹H NMR (500 MHz, CDCl₃) δ 3.32 (3H, s, OMe), 3.40-3.75 (9H, m), 3.82 (1H, dd, $J = 10.5$ and 3.0 Hz), 3.99 (1H, dd, $J = 9.5$ and 9.5 Hz, H-3), 4.18 (1H, dd, $J = 11.0$ and 2.0 Hz), 4.34 (1H, d, $J = 8.0$ Hz, H-1'), 4.47-4.60 (5H, m), 4.61 (1H, d, $J = 3.5$ Hz, H-1), 4.65 (1H, ABq, $J = 12.0$ Hz, ArCH₂), 4.71 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 4.74-4.82 (3H, m), 4.80 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 4.90 (1H, ABq, $J = 10.5$ Hz, ArCH₂), 4.96 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 4.97 (1H, ABq, $J = 11.5$ Hz, ArCH₂), 7.13-7.37 (35H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 55.2, 68.5, 69.0, 69.8, 73.3, 73.4, 74.9, 75.0 \times 2, 75.7 \times 2, 77.9, 78.0, 79.8, 82.0 \times 2, 84.8, 98.0, 103.8, 127.5, 127.6 \times 2, 127.7, 127.9 \times 3, 128.0 \times 2, 128.2, 128.4 \times 2, 128.5, 138.1 \times 2, 138.2, 138.3 \times 2, 138.6, 139.0; HRMS (ESI-TOF) m/z 1009.4460 (1009.4503 calcd for C₆₂H₆₆O₁₁Na [M+Na]⁺).




25 α

Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- α -D-galactopyranoside (25 α)²: Colorless syrup; R_f 0.67 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{28} +37.3^\circ$ (*c* 0.49, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.82-1.00 (2H, m), 1.08-1.34 (3H, m), 1.58-1.87 (6H, m), 3.21 (1H, dd, *J* = 9.5 and 6.0 Hz, OCH₂), 3.42 (1H, dd, *J* = 9.5 and 7.5 Hz, OCH₂), 3.48-3.55 (2H, m), 3.90-4.00 (3H, m), 4.03 (1H, dd, *J* = 9.5 and 4.0 Hz), 4.39 and 4.48 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.57 and 4.94 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 4.66 and 4.81 (2H, ABq, *J* = 12.5 Hz, ArCH₂), 4.73 and 4.85 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.79 (1H, d, *J* = 3.5 Hz, H-1), 7.21-7.42 (20H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.7, 25.8, 26.6, 30.0, 30.2, 37.5, 69.1, 69.2, 73.2, 73.4, 73.8, 74.1, 75.1, 79.1, 97.6, 127.7, 127.9, 128.2 \times 2, 128.3 \times 2, 138.1, 138.7, 138.8, 138.9; HRMS (ESI-TOF) *m/z* 659.3348 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).




25 β

Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- β -D-galactopyranoside (25 β)²: White solid; R_f 0.60 (3/1 *n*-hexane/EtOAc); $[\alpha]_D^{28} -7.2^\circ$ (*c* 1.45, CHCl₃); mp 101.8-102.8 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.86-1.04 (2H, m), 1.06-1.33 (3H, m), 1.58-1.90 (6H, m), 3.27 (1H, dd, *J* = 9.5 and 7.5 Hz, OCH₂), 3.47-3.62 (4H, m), 3.75 (1H, dd, *J* = 9.0 and 5.0 Hz, OCH₂), 3.80 (1H, dd, *J* = 10.0 and 7.5 Hz, H-2), 3.88 (1H, br d, *J* = 2.5 Hz, H-4), 4.32 (1H, d, *J* = 7.5 Hz, H-1), 4.40 and 4.45 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 4.62 and 4.93 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 4.70 and 4.76 (2H, ABq, *J* = 12.0 Hz, ArCH₂), 4.75 and 4.93 (2H, ABq, *J* = 11.5 Hz, ArCH₂), 7.23-7.38 (20H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.8 \times 2, 29.8, 30.2, 68.9, 73.1, 73.4, 73.5, 74.4, 75.2, 75.6, 79.6, 82.3, 104.2, 127.5, 127.7, 127.9, 128.1, 128.2, 128.3 \times 2, 128.4, 137.9, 138.6, 138.7 \times 2; HRMS (ESI-TOF) *m/z* 659.3322 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).




26 α

Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- α -D-mannopyranoside (26 α)³: Colorless syrup; R_f 0.60 (4/1 *n*-hexane/EtOAc); $[\alpha]_D^{25} +33.3^\circ$ (*c* 0.56, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 0.80-1.74 (11H, m), 3.15 (1H, dd, $J = 9.5$ and 6.0 Hz, OCH₂), 3.45 (1H, dd, $J = 9.0$ and 7.0 Hz, OCH₂), 3.68-3.81 (4H, m), 3.86-4.01 (2H, m), 4.48-4.79 (7H, m, ArCH₂), 4.82 (1H, d, $J = 1.5$ Hz, H-1), 4.87 (1H, ABq, $J = 11.0$ Hz, ArCH₂), 7.14-7.39 (20H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.7, 25.8, 26.5, 29.8, 30.0, 37.8, 69.3, 71.8, 72.2, 72.5, 73.1, 73.3, 74.9, 75.0, 75.2, 80.3, 97.9, 127.4, 127.5, 127.6, 127.7 \times 2, 127.8, 128.1, 128.2, 128.3 \times 2, 138.4, 138.5, 138.6; HRMS (ESI-TOF) m/z 659.3326 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).



26 β

Cyclohexylmethyl 2,3,4,6-tetra-*O*-benzyl- β -D-mannopyranoside (26 β)³: White solid; R_f 0.60 (4/1 *n*-hexane/EtOAc); $[\alpha]_D^{25} -49.0^\circ$ (*c* 0.92, CHCl₃); mp 64.5-66.0 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.83-1.87 (11H, m), 3.20 (1H, dd, $J = 9.0$ and 6.5 Hz, OCH₂), 3.44 (1H, ddd, $J = 8.0$, 6.5 and 4.0 Hz, H-5), 3.50 (1H, dd, $J = 9.5$ and 3.0 Hz, OCH₂), 3.71-3.92 (5H, m), 4.35 (1H, br s, H-1), 4.43 and 4.50 (2H, ABq, $J = 12.0$ Hz, ArCH₂), 4.53 and 4.91 (2H, ABq, $J = 11.0$ Hz, ArCH₂), 4.60 and 4.63 (2H, ABq, $J = 12.0$ Hz, ArCH₂), 4.87 and 5.00 (2H, ABq, $J = 13.0$ Hz, ArCH₂), 7.16-7.49 (20H, m, ArH); ¹³C NMR (500 MHz, CDCl₃) δ 25.9 \times 2, 26.6, 29.9, 30.1, 38.1, 69.7, 71.3, 73.4, 73.7, 75.0, 75.1, 75.8, 75.9, 82.4, 102.0, 127.3, 127.4, 127.5, 127.6, 128.1, 128.3 \times 2, 128.4, 138.2, 138.3, 138.5, 138.8; HRMS (ESI-TOF) m/z 659.3380 (659.3349 calcd for C₄₁H₄₈O₆Na [M+Na]⁺).



Cyclohexylmethyl 2-*O*-benzoyl-3,4,6-tri-*O*-benzyl- β -D-glucopyranoside (27 β): White solid; R_f 0.40 (4/1 *n*-hexane/EtOAc); $[\alpha]_D^{26} +19.9^\circ$ (*c* 1.50, CHCl₃); mp 83.0-84.0 °C; ¹H NMR (500 MHz, CDCl₃) δ 0.69-0.84 (2H, m), 0.90-1.12 (3H, m), 1.40-1.63 (6H, m), 3.22 (1H, dd, *J* = 9.7 and 6.9 Hz, OCH₂), 3.52-3.58 (1H, m), 3.66-3.85 (3H, m), 3.78 (1H, dd, *J* = 9.0 and 2.0 Hz, H-4), 3.81 (1H, dd, *J* = 9.2 and 9.2 Hz, H-3), 4.47 (1H, d, *J* = 8.0 Hz, H-1), 4.58 and 4.82 (2H, ABq, *J* = 10.6 Hz, ArCH₂), 4.59 and 4.65 (2H, ABq, *J* = 12.3 Hz, ArCH₂), 4.67 and 4.74 (2H, ABq, *J* = 11.2 Hz, ArCH₂), 5.27 (1H, dd, *J* = 9.5 and 8.0 Hz, H-2), 7.08-8.06 (20H, m); ¹³C NMR (500 MHz, CDCl₃) δ 25.6, 26.4, 29.5, 29.6, 37.7, 68.8, 73.5, 73.9, 74.9, 75.0, 75.2, 75.5, 78.1, 82.7, 101.5, 127.6, 127.7, 127.8, 128.0 \times 2, 128.2, 128.3 \times 2, 128.4, 129.7, 130.1, 132.9, 137.8, 137.9, 138.1, 165.2; HRMS (ESI-TOF) *m/z* 673.3127 (673.3141 calcd for C₄₁H₄₆O₇Na [M+Na]⁺).

References

1. H. Nagai, K. Sasaki, S. Matsumura and K. Toshima, *Carbohydr. Res.*, 2005, **340**, 337.
2. T. Iimori, T. Shibasaki and S. Ikegami, *Tetrahedron Lett.*, 1996, **37**, 2267.
3. K. Toshima, H. Nagai, K. Kasumi, K. Kawahara and S. Matsumura, *Tetrahedron*, 2004, **60**, 5331.

^1H and ^{13}C NMR spectra




Figure S1 ¹H NMR spectrum of **9a**




Figure S2 ¹³C NMR spectrum of **9a**




Figure S3 ^1H NMR spectrum of **9 β**




Figure S4 ^{13}C NMR spectrum of **9 β**




Figure S5 ¹H NMR spectrum of **17a**




Figure S6 ¹³C NMR spectrum of **17a**




Figure S7 ^1H NMR spectrum of **17 β**




Figure S8 ^{13}C NMR spectrum of **17 β**




Figure S9 ¹H NMR spectrum of **18 α**




Figure S10 ¹³C NMR spectrum of **18 α**




Figure S11 ¹H NMR spectrum of **18β**




Figure S12 ¹³C NMR spectrum of **18β**




Figure S13 ^1H NMR spectrum of **19 α**




Figure S14 ^{13}C NMR spectrum of **19 α**




Figure S15 ¹H NMR spectrum of **19β**




Figure S16 ¹³C NMR spectrum of **19β**




Figure S17 ¹H NMR spectrum of **20 α**




Figure S18 ¹³C NMR spectrum of **20 α**




Figure S19 ¹H NMR spectrum of **20β**




Figure S20 ¹³C NMR spectrum of **20β**




Figure S21 ¹H NMR spectrum of **21α**




Figure S22 ¹³C NMR spectrum of **21α**




Figure S23 ^1H NMR spectrum of **21 β**




Figure S24 ^{13}C NMR spectrum of **21 β**




Figure S25 ^1H NMR spectrum of **25 α**




Figure S26 ^{13}C NMR spectrum of **25 α**




Figure S27 ^1H NMR spectrum of **25 β**




Figure S28 ^{13}C NMR spectrum of **25 β**




Figure S29 ¹H NMR spectrum of **26a**




Figure S30 ¹³C NMR spectrum of **26a**




Figure S31 ¹H NMR spectrum of **26β**




Figure S32 ¹³C NMR spectrum of **26β**




Figure S33 ¹H NMR spectrum of **27β**




Figure S34 ¹³C NMR spectrum of **27β**




Figure S35 ¹H NMR spectrum of recovered **2** (500 MHz, CDCl₃)




Figure S36 ¹³C NMR spectrum of recovered **2** (500 MHz, CDCl₃)




Figure S35 ¹H NMR spectrum of recovered **5** (500 MHz, acetone-*d*₆)




Figure S36 ¹³C NMR spectrum of recovered **5** (500 MHz, acetone-*d*₆)